Home > Insider Trading > Filing (0000950142-10-000387)

Filing Details

Accession Number:: 0000950142-10-000387
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-03-08 12:00:00
Reporting Period:: 2010-03-04

Filing Date:: 2010-03-08
Accepted Time:: 2010-03-08 20:47:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1401923	Map Pharmaceuticals Inc.	MAPP	Pharmaceutical Preparations (2834)	200507047

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
927752	H Frank Pearl	2099 Pennsylvania Avenue Nw Suite 900 Washington DC 20006		No	No	Yes	No
1253323	Perseuspur Llc	2099 Pennsylvania Ave Nw Ste 900 Washington DC 20006		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2010-03-04	677	$14.15	2,868,472	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2010-03-04	14	$14.15	2,868,472	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2010-03-04	3,061	$14.15	2,868,472	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2010-03-04	10,553	$14.27	2,868,472	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2010-03-05	4,616	$13.95	2,842,887	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2010-03-05	97	$13.95	2,842,887	No	4	S	Indirect	See Footnotes
Common Stock	Disposition	2010-03-05	20,872	$13.95	2,842,887	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Footnotes

The price shown in Column 4 is a weighted average sale price. The price range for the sales is $14.00 to $14.23. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
All of the securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, LP ("Perseus-Soros"), Perseus-Soros Partners, LLC ("Perseus-Soros Partners"), the general partner of Perseus-Soros, Perseus Biotech Investment, LLC ("PBI"), Perseus Biotech Fund Partners, LLC ("Perseus Biotech Fund Partners"), Biotech Management Partners, LLC ("Biotech Management Partners"), Perseus, L.L.C. ("Perseus"), Perseuspur, L.L.C. ("Perseuspur"), Perseus 2000 Biotech Satellite, LLC ("Perseus Satellite") and Frank H. Pearl. Perseus BioTech Fund Partners is a managing member of Perseus-Soros Partners and Biotech Management Partners. Perseuspur is the managing member of Perseus, PBI, Perseus Biotech Fund Partners and the entity that controls Perseus Satellite. Frank H. Pearl is the managing member of Perseuspur.
Represents 677 shares of the Issuer's Common Stock sold by Perseus-Soros Partners. After the sale, Perseus-Soros Partners owned directly 4,616 shares of the Issuer's Common Stock.
Represents 14 shares of the Issuer's Common Stock sold by PBI. After the sale, PBI owned directly 97 shares of the Issuer's Common Stock.
Represents 3,061 shares of the Issuer's Common Stock sold by Biotech Management Partners. After the sale, Biotech Management Partners owned directly 20,872 shares of the Issuer's Common Stock.
Represents 10,553 shares of the Issuer's Common Stock sold by Perseuspur. After the sale, Perseuspur owns directly 13,925 shares of the Issuer's Common Stock.
The price shown in Column 4 is a weighted average sale price. The price range for the sales is $13.70 to $14.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price
Represents 4,616 shares of the Issuer's Common Stock sold by Perseus-Soros Partners. After the sale, Perseus-Soros Partners directly owns no shares of the Issuer's Common Stock.
Represents 97 shares of the Issuer's Common Stock sold by PBI. After the sale, PBI directly owns no shares of the Issuer's Common Stock.
Represents 20,872 shares of the Issuer's Common Stock sold by Biotech Management Partners. After the sale, Biotech Management Partners directly owns no shares of the Issuer's Common Stock.